tirzepatide naion risk Is (a GIP/GLP‑1 dual agonist) safe to initiate in a patient with a history of anterior ischemic optic neuropathy (AION) or other factors for optic nerve ischemia? GLP-1 medicine and non-arteritic anterior

The HR for any psychiatric disease was 1.98 (95% CI: 1.942.01)

For many patients, the cardiovascular, metabolic, and quality of life benefits outweigh the manageable risks to oral health

Anti-Inflammatory Effects Chronic intermittent hypoxia and sleep fragmentation in OSA lead to systemic and local inflammation [1]

It's like comparing sprinterssure, one might have a faster record, but on any given day, either could win the race

Signs Microdosing Is Not Working (Or Not Safe) People who attempt microdosing often report: No appetite changes No weight loss Unpredictable digestion Feeling worse on some days Random nausea Slower progress Needing to restart dosing again later This happens because microdosing interferes with how tirzepatide is designed to work

241 DPP-4 cleaves GLP-1(7-36) at the 8th position, generating GLP-1(936)